Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

ASPR’s Portfolio of COVID-19 Medical Countermeasures under Investigation

There are no drugs or other therapeutics presently approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. However, ASPR is sponsoring the development of a number of therapeutic products that are being made available under either FDA’s expanded access program and/or have been granted an Emergency Use Authorization by FDA.

Therapeutic Products

1. Veklury (Remdesivir) (Gilead Sciences, Inc.) Convalescent plasma (Multiple Contracts) Chloroquine or hydroxychloroquine (Multiple Contracts)

Diagnostic Tests 

Point-of-Care COVID019 Cue Health Monitoring System & Mobile App (Cue Health Inc) Accula SARS-CoV-2 Test (Mesa Biotech) Xpert Xpress SARS-CoV-2 Test (Cepheid) Panther Fusion SARS-CoV-2  Assay (Hologic) NxTag CoV Extended Panel Assay (Luminex)  Aries SARS-CoV-2 Test (Luminex) 8.    LIASON SARS-CoV-2 S1/S2 IgG (DiaSorin Inc.) QIAstat-Dx RPS2  (Qiagen) 1. Cepheid – Xpert Xpress SARS-COV-2/Flu/RSV test 2. GenMark Diagnostics, Inc. – ePlex Respiratory Pathogen v2 Panel Hologic, Inc. – Aptima® SARS-CoV-2-assay Qiagen, LLC – QIAstat-Dx Respiratory SARS-CoV-2 Panel Siemens Healthineers – ADVIA Centaur® SARS-CoV-2 Total (CoV2T) assay 6. Siemens Healthineers – Atelica® IM SARS-CoV-2 Total (COV2T) assayVela Diagnostics USA, Inc. – ViroKey™ SARS-CoV-2RT-PCR Test 


  • This page last reviewed: October 26, 2020